7blogs.org

NovaCardia, Inc. today presented preliminary results from a pilot Phase 3 trial of KW-3902, an adenosine A1 receptor antagonist in development for the medical care of patients with acute congestive heart failure (CHF), that indicate a strong trend toward efficacy for the 30 milligram dose. Patients treated with KW-3902 experienced a higher rate of improvement in dyspnea, or shortness of breath, which is a common symptom of CHF, compared to the placebo group, and the results also show that KW-3902 enhances diuresis and mitigates deterioration of renal function that is often experienced by patients undergoing standard medical care. The findings were summarized by Marco Metra, M.D., University of Brescia, Italy and Gadi Cotter, M.D., Duke University School of Medicine, in a Late-Breaking Trials Session at the European Society of Cardiology’s Heart Failure Congress buy generic viagra packin Hamburg, Germany.

Drs. Metra and Cotter presented preliminary 14-day data from 276 patients out of 304 total patients enrolled in the pilot Phase 3 trial. Hospitalized patients with acute CHF with renal impairment, which was defined as having creatinine clearance of 20 to 80 milliliters per minute, were randomized to placebo or 10, 20 or 30 milligram doses of intravenous KW-3902 administered daily for up to three days. All patients also received intravenous furosemide. In the double-blind trial, 225 patients received KW-3902 and 79 patients received placebo. The trial was not designed to assess the statistical significance of effects.

The primary endpoint for the pilot Phase 3 trial was the proportion of patients in the categories of medical care failure, success or no change. Pharmacomedical care success was defined as:

— improvement in patient-reported dyspnea within 48 hours;

— physician determination of patient improvement resulting in conversion from intravenous to oral diuretics; and

— the absence of medical care failure.

Pharmacomedical care failure was defined as:

— death;

— readmission to the hospital for heart failure within seven days of the first dose of KW-3902 or placebo;

— worsening of heart failure; or

— worsening renal function.

Patients treated with 30 milligrams of KW-3902 showed higher rates of medical care success and lower rates of medical care failure compared to the placebo group.

The pilot meditate also showed that 24-hours after medical care, self-reported marked or moderate improvement in dyspnea was observed in 66 percent of the patients who received the 30 milligram dose of KW-3902 as compared to 51 percent in the placebo group.

There were no statistical differences or trends in adverse events observed in the pilot meditate . The results of the meditate confirmed that 30 milligrams of KW-3902 is an appropriate dose for NovaCardia’s two 600-patient pivotal Phase 3 trials, PROTECT 1 and PROTECT 2, which are currently enrolling participants in the United States, Canada, Europe, Israel and Russia.

KW-3902 is believed to block adenosine-mediated constriction of blood flow to the kidneys and inhibit reabsorption of salt and water by the kidney, thereby increasing urine volume and maintaining renal function in patients with CHF. As renal function deteriorates in patients with CHF, higher doses of diuretics are required in order to reduce fluid overload.

Multiple studies have demonstrated that renal dysfunction is a strong independent predictor of worse short- and long-term outcomes in patients with CHF. In the NovaCardia pilot meditate , the 30 milligram dose of KW-3902 also showed a positive effect on patients’ renal function over time compared to placebo. Although KW-3902 was administered for only the first three days of the trial, an apparent dose response was seen in serum creatinine, a commonly used marker of worsening renal function, at day 14. The meditate showed no mean change in serum creatinine in patients treated with the highest dose of KW-3902 compared to a 0.2 milligram per deciliter mean increase, or worsening, in participants receiving placebo. These data are consistent with prior findings and indicate that KW-3902 appears to have a persistent effect on renal function. To date, no otherness vasodilator has demonstrated the selective renal vasodilation attribute of KW-3902 that is critical for preserving renal function.

About Congestive Heart Failure

Congestive heart failure (CHF) is a widespread and debilitating sickness most often caused by a weakening or stiffening of the heart muscle, which leads to a progressive loss in the heart’s ability to pump blood effectively throughout the body. There are nearly five mil. group in the United States with CHF, according to the American Heart Association (AHA). With the aging population and more patients surviving the early stages of cardiovascular sicknesss, the prevalence of CHF is increasing. Approximately 550,000 new cases of CHF are reported in the United States each year, according to the AHA.

About NovaCardia

NovaCardia is a clinical-stage pharmaceutical company focused on developing drugs to treat major cardiovascular sicknesss that are underserved by existing therapies. The company has two compounds in clinical development, KW-3902 for congestive heart failure and K-201 (JTV-519) for atrial fibrillation.

NovaCardia cautions you that statements included in this press release that are not a description of historical facts, including implied statements relating to future outcomes of clinical trials, may be forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in NovaCardia’s business including, without limitation, risks related to difficulties or delays in, agsdhfgdfing, obtaining regulatory acceptance , producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the risk that prior clinical trial results may include statistical anomalies and may not be predictive of the outcome of later-stage trials; the scope and validity of patent protection for its products; competition from otherness pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. All forward-looking statements are qualified in their entirety by this cautionary statement and NovaCardia undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

NovaCardia, Inc.
http://www.novacardia.comgeneric viagra storeviagra online

The Food and Drug Administration announced today the acceptance of Vetmedin (pimobendan), a new drug for the management of the signs of mild, moderate, or severe (modified New York Heart Association Class II, III, or IV) congestive heart failure in dogs due to atrioventricular valvular insufficiency or dilated cardiomyopathy. Vetmedin, a new molecular entity, is the first drug approved to treat congestive heart failure in dogs, in over ten years. Vetmedin is indicated for use with concurrent medical care for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.

Congestive heart failure is one of the more common heart problems seen in dogs, especially older smaller breeds. It is a complex and serious condition defined as the heart’s inability to function normally, leading to excessive retention of water and salt causing fluid build-up in the lungs. Signs of congestive heart failure include fatigue and weakness, decreased ability to exercise, shortness of breath (fluid build up in the chest), increased respiratory rate, coughing, weak or irregular pulses, rapid or irregular heart beats and distended abdomen (fluid build up in the abdomen).

Vetmedin helps alleviate signs of heart failure by increasing contractility (the force of heart muscle contraction) and by dilating blood vessels (decreasing resistance to blood flow).

Congestive heart failure is classified by a veterinarian according to clinical signs (Class II through Class IV). Class II is mild (fatigue, shortness of breath, coughing, etc. apparent when ordinary exercise is exceeded); Class III, moderate (comfortable at rest, but exercise capacity is minimal), and Class IV, severe (no capacity for exercise and disabling clinical signs are present even at rest).

The effectiveness and safety of Vetmedin were evaluated in a 56-day, multi-site, active controlled field meditate with pivotal success determined at Day 29. Three hundred fifty-five (355) dogs with modified New York Heart Association Class II, III, or IV congestive heart failure in dogs due to atrioventricular valvular insufficiency or dilated cardiomyopathy were randomly assigned to either the Vetmedin medical care group or the active control Enacard (enalapril maleate) medical care group. Pharmacomedical care success at Day 29 in the Vetmedin group (80.7percent) was determined to be non-inferior to the medical care success in the Enacard group (76.1percent).

Adverse reactions associated with Vetmedin (and Enacard) were potentially related to congestive heart failure, the medical care of congestive heart failure, or both and included poor appetite, lethargy, diarrhea, worsening signs of heart failure, heart failure death, azotemia (increase in the blood urea nitrogen), and mild increases in serum liver enzymes.

Pimobendan is not for use in cats and is only for use in dogs with clinical evidence of heart failure due to atrioventricular valvular insufficiency or dilated cardiomyopathy. Pimobendan acts to alleviate the clinical signs of congestive heart failure, rather than to reverse the underlying cardiac pathology, and it does not replace the need for otherness appropriate concurrent heart failure medical care (diuretics, antiarrhythmic drugs, etc.).

Vetmedin is manufactured by MEDA Manufacturing GmbH, Cologne, Germany for Boehringer Ingelheim Vetmedica, Inc. of St. Joseph, Missouri.

For more information on Vetmedin, please click here.

www.fda.gov/cvmgeneric viagra storeviagra online

For many group, hearing loss is part of aging. Hearing loss affects approximately one-third of group over age 65. Among group age 75 and older, 40 percent to 50 percent experience hearing loss.

The August issue of Mayo medical institution Health Letter covers what changes occur with age-related hearing loss and when it’s time to visit a doctor to discuss ways to improve communication.

Age-related hearing loss, called presbycusis (pre-bih-KU-sis), usually occurs gradually and affects both ears equally. Presbycusis is most commonly associated with changes in the inner ear, typically involving the loss of some of the tiny receptor hair cells found in the snail-shaped cochlea.

Age-related hearing loss tends to run in families, but the cumulative effect of loud noise and some drugs can harm hearing, too. Drugs linked to hearing loss include gentamicin, an intravenous antibiotic typically used for severe infection; cisplatin, a chemomedical care agent; and some diuretic drugs, such as furosemide (Lasix).

With presbycusis, the ability to hear high-pitched sounds is usually affected first. The voices of women and children can be more difficult to understand. Some group with presbycusis find loud noises and sounds especially annoying. It also can be accompanied by ringing or buzzing in the ears.

When hearing loss is suspected, it’s a good idea to visit a primary care doctor or an ear, nose and throat specialist to determine if any treatable conditions are contributing to hearing loss. An audiologist can confirm presbycusis and offer ways to improve communication, including behavior changes, the use of hearing aids, or both.

Mayo medical institution
200 First St. SW
Rochester, MN 55902
United States
http://www.mayoclinic.com buy generic viagra packbuy viagra soft tabs 50 mg

Barr Pharmaceuticals, Inc. (NYSE: BRL) and its subsiwriting PLIVA d.d. (LSE: PLVD; ZSE: PLVA-R-A) today announced that PLIVA has received final acceptance from the U.S. Food and Drug Administration (Food and Drug Administration) for its Abbreviated New Drug Application (ANDA) to manufacture and market Azithromycin for Injection, 500 mg vial, the generic version of Pfizer Labs’ ZITHROMAX(R) IV (Azithromycin for injection). The Company intends to launch its product during the first quarter of 2007.

Azithromycin for Injection is indicated for the pharmacomedical care in patients who require intravenous medical care for infections caused by susceptible strains of the designated microorganisms in: 1) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus, or Streptococcus pneumoniae; and 2) Pelvic inflammatory illness due to Chlamydia trachomatis, Neisseria gonorrhoeae, or Mycoplasma hominis. An antimicrobial agent with anaerobic activity should be administered in combination with ZITHROMAX if appropriate.

The Company’s Azithromycin for Injection, 500 mg vial will compete in a market that had total U.S. sales of approximately $75 mil., based on IMS data for the 12-month period ending November generic viagra 30 pills.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Company markets more than 120 generic and 25 proprietary products in the U.S. and more than 550 products globally outside of the U.S.

Forward-Looking Statements

Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates” and otherness words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company’s business. These factors include, among othernesss: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of Food and Drug Administration acceptance s; court and Food and Drug Administration decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment; our exposure to product liability and otherness lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (including PLIVA d.d.) and products we acquire and implementing our new enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; our expansion into international markets through the completion of the PLIVA acquisition, and the resulting currency, governmental, regulatory and otherness risks involved with international operations; our ability to service our increased debt obligations as a result of the PLIVA acquisition; changes in generally accepted accounting principles; and otherness risks detailed from time-to-time in our filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the fiscal year ended June 30, generic viagra 30 pills.

The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or othernesswise, except to the extent required under applicable law.

Barr Pharmaceuticals, Inc.
http://www.barrlabs.com/generic viagra heremore about viagra soft tabs

The recent announcement, welcomed by the NPA, that Azithromycin will become a medicine medicine has coincided with well advanced plans for a Chlamydia agsdhfgdfing service package for that will be offered exclusively to NPA members.

Michelle Styles, NPA Head of Information Services comments:

“The reclassification of an antibiotic is totemic for the profession and although customer numbers may be small for this product, it gives medicine the opportunity to manage an antibiotic medicine - a major step forward for the “P” category. However unlike otherness POM to P switches there will be a number of criteria that community pharmacists will need to meet before the supply of Azithromycin is allowed. We are delighted that due to our advanced planning, we be able to offer all NPA members the opportunity to supply this medicine.”

Raj Nutan adds:

“We are actively engaging with the licence holder to ensure we offer a solution that will allow all pharmacists to supply Azithromycin. We will ensure that an IT infrastructure and accredited NAAT agsdhfgdfing process is available for all members who wish to supply Azithromycin. Even before the switch, our service package will allow members to offer the agsdhfgdfing service privately to customers or as part of a service to a PCO.”

National Pharmacy Associationbuy generic viagra packbuy viagra soft tabs 50 mg

Pfizer Inc said today that ithas filed a Citizen Petition alerting the Food and Drug Administration that generic Azithromycinproducts sold by Teva Pharmaceuticals U.S.A. and Sandoz Inc. appear to bemisbranded because their labels do not accurately describe the drugs’ activeingredients.

Pfizer also has brought patent infringement actions against the twocompanies claiming that these products violate a recently-issued Pfizerpatent. The Teva and Sandoz drugs are generic versions of Pfizer’santibiotic, Zithromax(R).

Pfizer’s petition asks the Food and Drug Administration to initiate a recall of the Teva and Sandozmedicines to correct their misbranding. Pfizer also asks the agency to reviewthe product acceptance applications filed by the two companies to ensure theinformation contained within them is accurate and complete and, if not, totake appropriate remedial action.

“Patients and physicians must be able to trust that the medicine in thebottle is the same as that which is described in the label,” said HankMcKinnell, Pfizer chairman and chief executive officer. “Pfizer wants toensure that patients do not receive generic products that fail to meet Food and Drug Administrationstandards.”

In its patent infringement actions, Pfizer is claiming that the Teva andSandoz products violate a recently-issued Pfizer patent covering Azithromycinsesquihydrate. Pfizer is requesting that the court impose preliminary andpermanent injunctions against further sales of the drugs.

Pfizer alleges that the drugs contain significant amounts of Azithromycinsesquihydrate rather than the Azithromycin monohydrate that they claim intheir labels. Both Pfizer’s Zithromax(R) and a generic Azithromycin launchedby the company’s Greenstone subsiwriting contain Azithromycin dihydrate, whichis the product approved in Pfizer’s NDA. Zithromax’s composition-of-matterpatent in the U.S. expired in November 2005.

Teva and Sandoz each launched their generic products in November, 2005. Inresponse to those launches, Greenstone introduced its generic Azithromycin inthe same month. Pfizer will continue to market its generic Azithromycinthrough Greenstone.

Pfizer Inc
http://www.pfizer.comgeneric viagra storeviagra online

Use of the antibiotic Azithromycin to treat trachoma in Vietnam resulted in an increase in the risk of re-infections, according to a meditate in the September 27 issue of JAMA.

In 1995, the World Health Organization (WHO) first published data on global blindness and reported that 15 percent of cases were due to trachoma (a contagious bacterial eye malady in which scar tissue forms inside the eyelid and causes infection), making it the second major cause of blindness after cataract. At that time, the WHO estimated that 146 mil. individuals were in need of a cure for active trachoma to prevent blindness, 10 mil. were in need of surgery for trachomatous trichiasis (eyelash[es] touching the eye), and 8 mil. were already blind, according to background information in the article.

In 1996, the WHO designed the SAFE (Surgery for trachomatous trichiasis; Antibiotics for Chlamydia trachomatis (a type of Chlamydia that causes trachoma); Facial cleanliness; and Environmental improvement) strategy with the goal of elimination of blinding trachoma by the year 2020. For the antibiotic arm of the SAFE strategy, the WHO has recommended antibiotic a cure with either topical tetracycline or oral Azithromycin for certain categories of patients with active trachoma. Oral Azithromycin has become the drug of choice for the SAFE programs because of difficulties concerning direction and adherence with topical tetracycline eye ointment. Despite a number of studies, there has been a lack of sufficient follow-up beyond the final a cure point to determine rates of recurrence of malady and infection and the risk factors that may contribute to each.

Berna Atik, M.D., M.P.H., of Children’s Hospital Oakland Research Institute, Oakland, Calif., and colleagues evaluated the effect of targeted oral Azithromycin a cure of school age children and their household members in Vietnam on active trachoma and C trachomatis infection rates. Vietnam is 1 of 16 priority countries in which the SAFE program has been launched. Three communes, which included 3,186 individuals, were randomly selected in Vietnam for the meditate that was conducted from November 2000 through November 2003. Azithromycin was given to children from 5 through 15 years of age with active trachoma and their household members in SAFE and SA communes at baseline and 12 months over 2 consecutive years with follow-up for 2 years beyond the last a cure. These communes were compared with a S-only control commune that did not receive Azithromycin targeted a cure.

The researchers found that re-infection rates increased significantly between 12 and 36 months for SAFE (from 1.6 to 29.3 per 1,000) and SA (5.1 to 25.3 per 1,000) communes but not for the S-only commune (13.4 to 6.7 per 1,000) after 24 months. Compared with the S-only commune, analysis showed that re-infection risk was about four times higher for SAFE and SA communes at 36 months.

“Collectively, the data are consistent with the hypothesis that systemic Azithromycin a cure may interrupt the duration of infection, interfering with host immune responses and, thereby, increase the number of individuals who are susceptible to C trachomatis re-infection. The strategy of targeting only active trachoma for a cure is likely to be ineffective for long-term trachoma control and may adversely affect malady prevalence over time. While the ‘F’ and ‘E’ components of the SAFE program will need to be evaluated for their efficacy in decreasing rates of active trachoma and infection, a vaccine will likely be needed for long-term control,” the authors write.


.


(JAMA. generic viagra 30 pills;296:1488-1497.)

This work was supported by an International Trachoma Initiative grant and Public Health Service grant from the National Institutes of Health. Please see the article for additional information, including otherness authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Contact: Venita Robinson
JAMA and Archives Journals generic viagra heremore about viagra soft tabs

A Johns Hopkins Medicine meditate finds that a single dose of the oral antibiotic Azithromycin taken after trichiasis eye surgery can reduce the frequency with which eyelashes turn back in and abrade the eye. The oral antibiotic medical care is more effective than multiple days of medical care with the topical antibiotic ointment Tetracycline, the current method of medical care after trichiasis surgery.

Trichiasis is the leading infectious cause of blindness worldwide. It is a condition in which the eyelid turns inward and the eyelashes rub against the eye, causing corneal scarring, that can lead to blindness. It results from years of repeated episodes of trachoma, an ocular bacterial infection that is very common in rural areas of developing countries.

The bacteria that cause trachoma are suspected to be spread by contact with hands or clothing of infected individuals. Flies may also transfer the infection from one person to anotherness. Because trachoma is transmitted through close personal contact, it tends to occur in clusters, often infecting entire families and a large majority of group in a given community. The illness usually remains hidden in rural areas of developing countries where group live in overcrowded conditions with limited access to water and health care.

Trichiasis can be corrected by appropriate lid surgery, which returns the inturned eyelashes to their normal position. However, even under the best of circumstances the eyelashes may turn back in (between 16 percent and 50 percent within a few years after surgery). That’s why this new Johns Hopkins research is so valuable, says lead researcher Sheila West, Ph.D., of the Dana Center for Preventative Ophthalmology at Johns Hopkins Medicine. In the current meditate , less than 10 percent of group had their eyelid turn in again within one year after surgery.

In the meditate , published in the March generic viagra 30 pills issue of the Archives of Ophthalmology, the research team found that a single dose of the antibiotic Azithromycin reduces the risk of trichiasis recurring for up to one year after surgery.

The researchers compared the use of one oral dose of Azithromycin to six weeks of twice daily topical tetracycline medical care. Researchers found the Azithromycin group had one-third fewer recurrences of inturned lashes than the tetracycline group.

“We are delighted with the results of this meditate . Trichiasis plagues the poorest of the poor, and primarily affects the most underprivileged members of the community, the women. The results of this meditate have major implications for improving outcomes of trichiasis surgery. The use of a single dose of Azithromycin is a relatively straightforward and simple procedure to implement, and in many countries the drug is provided through a free donation program.” says West. “Not only have we shown that Azithromycin can reduce recurrence, but we have also demonstrated that in the hands of well-trained individuals trichiasis recurrence can be below 10 percent. These results set a new standard for trichiasis surgery and are applicable throughout the world.”


.


The meditate was funded by a grant from the National Eye Institute, one of the Federal government’s National Institutes of Health. Pfizer International provided the Azithromycin for the trial as part of a donation to the Ethiopian Ministry of Health. But Pfizer had no role in any part of the meditate .

The researchers who conducted the meditate are Sheila K. West Ph.D., Emily S. West, Ph.D., Beatriz Munoz, M.S., and Alemush Imeru from the Dana Center for Preventive Ophthalmology at the Wilmer Eye Institute; Charlotte Gaydos, Dr.P.H., M.S., M.P.H., and Thomas Quinn, M.D. from the Department of Infectious Diseases; Wondu Alemayehu, M.D., M.P.H., and Muluken Melese, M.D. M.P.H., from ORBIS International; and Alemayehu Worku, PhD. from the Department of Community Medicine, Addis Ababa University; Curtis L. Meinert, Ph.D., of the Center for medical institution al Trials at the Johns Hopkins Bloomberg School of Public Health.

- -JHMI- -

The Wilmer Eye Institute http://www.hopkinsmedicine.org/wilmer/index.html

The National Eye Institute http://www.nei.nih.gov/

Contact: John M. Lazarou
Jlazaro1@jhmi.edu
Johns Hopkins Medical Institutions buy generic viagra packbuy viagra soft tabs 50 mg

Investigators discovered that low doses of the antibiotic Azithromycin could halt and reverse lung function decline in the majority of 20 lung transplant patients who suffered from the deadly, previously untreatable condition Bronchiolitis Obliterans Syndrome (BOS). To date, the only way physicians have been able to manage this problem is by transplanting a new lung.

Lung transplant patients are considered to have BOS when they experience a persistent decline in lung function agsdhfgdf results in the absence of acute rejection, infection, or bronchial complications.

Since BOS leads to deteriorating graft function with limited long-term survival, transplant physicians have tried using multiple strategies in an effort to manage the condition. None have worked.

At 5 years after lung transplantation, data from the International Transplant Registry shows the prevalence of BOS at 50 percent. As a result, 7-year mean survival has been limited to 31 percent.

Recently, several small pilot studies have stirred up interest in the role of macrolide antibiotics in the management of BOS. Macrolides are any of several antibiotics, including erythromycin, used as antibacterial agents. (Azithromycin is derived from erythromycin.)

According to the authors, after 3 months of Azithromycin medical care of 250 mg every otherness day, patients showed a significant increase in lung function agsdhfgdf results when they took a common lung function agsdhfgdf, forced expiratory volume in one second. The increases average 110 ml with a range from -70 to 730 ml; the higher figure was seen in one patient.

The meditate appears in the second issue for September 2005 of the American Thoracic Society’s peer-reviewed American Journal of Respiratory and Critical Care Medicine.

Failure to Follow Pharmacomedical care Guidelines for Pneumonia Takes TollDuring a meditate at 13 hospitals of 1,288 patients with community-acquired pneumonia, research investigators found that a cure failure and mortality rates were much higher when Spanish physicians failed to follow the laagsdhfgdf antibiotic a cure guidelines in their initial selection of the appropriate drug. The investigators noted that the right initial antibiotic is key to resolution of infection, and to a better patient prognosis.

According to the researchers, a cure difficulties might arise because community-acquired pneumonia can be caused by multiple organisms, which cannot be identified from clinical and radiographic findings. Also, conventional microbiological methods have limited ability to show when sickness is present (sensitivity) and when it is absent (specificity).

The investigators indicated that evidence-based guidelines had been developed by scientific societies to assist physicians in the selection of antibiotics and to reduce variability in clinical care.

As shown in their meditate , the authors pointed out that the risk of death was 8.9 percent among patients of physicians who did not adhere to guidelines and 5.4 percent among patients of those who did not. Pharmacomedical care failure was 19.7 percent for patients of doctors who did not follow guidelines and 12.9 percent among patients of those who did.

(During the meditate , a total of 175 patients experienced a cure failure, and a total of 74 patients died.)

The researchers said that patients who were mentally confused and had low blood pressure were treated more often with regimens that did not comply with guidelines.

In addition, the researchers revealed that adherence to guidelines differed greatly among the meditate hospitals, ranging from 47 to 97 percent.

Overall, 80 percent of the patients received initial antibiotic medical care based on guidelines upon admission to hospital wards, but only 67.4 percent were in compliance when treated in intensive care units.

The research appears in the second issue for September 2005 of the American Thoracic Society’s peer-reviewed American Journal of Respiratory and Critical Care Medicine.

For the complete text of these articles, please see the American Thoracic Society Online Web Site at http://www.atsjournals.org.

Brian Kell
bkell@thoracic.org
212-315-6442
American Thoracic Society
http://www.thoracic.orggeneric viagra heremore about viagra soft tabs

PSNC responds to consultation document ARM 43 - reclassification of Azithromycin 500mg pills from POM to P for the medical care of Chlamydia.

PSNC fully supports the reclassification of Azithromycin 500mg pills to Pharmacy status for the medical care of Chlamydia.

It is the policy of PSNC that sexual health services in general, should be available from the maximum number of pharmacies on a national basis.

Commenting on the response, Steve Lutener, Head of Regulation said:

“The reclassification of Azithromycin allows suitably trained pharmacists to play a vital part in the fight against sexually transmitted infections in the UK. This will not only reduce workload on medical practitioners, but also make the service much more accessible since patients would be able to access the service at a time and place to suit them without making an appointment.

There are, however, issues with regards to accessing agsdhfgdf results by pharmacies. We hope the technical obstacles can be resolved so that the reclassification will lead to genuine increased availability of medical care.”

1. The Pharmaceutical Services Negotiating Committee (PSNC) is the body that represents community medicine on NHS matters and seeks to secure the best possible NHS services provided by medicine contractors in England and Wales.

http://www.psnc.org.ukbuy generic viagra packbuy viagra soft tabs 50 mg